| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 13 |
| 1 | ATEZOLIZUMAB | 6 |
| 2 | NIVOLUMAB | 5 |
| 3 | DURVALUMAB | 4 |
| 4 | IPILIMUMAB | 4 |
| 5 | AVELUMAB | 3 |
| 6 | ADALIMUMAB | 1 |
| 7 | ADALIMUMAB-AATY | 1 |
| 8 | ADALIMUMAB-ADAZ | 1 |
| 9 | ADALIMUMAB-FKJP | 1 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NIVOLUMAB AND RELATLIMAB-RMBW | 1 | 0.0019 |
| 1 | AVELUMAB | 3 | 0.0007 |
| 2 | DURVALUMAB | 4 | 0.0002 |
| 3 | ATEZOLIZUMAB | 6 | 0.0002 |
| 4 | PEMBROLIZUMAB | 13 | 0.0001 |
| 5 | IPILIMUMAB | 4 | 0.0001 |
| 6 | NIVOLUMAB | 5 | 0.0001 |
| 7 | DABRAFENIB | 1 | 0.0000 |
| 8 | TRAMETINIB | 1 | 0.0000 |
| 9 | MIDAZOLAM HYDROCHLORIDE | 1 | 0.0000 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lymphocyte Activation Gene-3 Blocker [EPC] | 1 | 0.0019 |
| 1 | Programmed Death Ligand-1 Blocker [EPC] | 4 | 0.0002 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 17 | 0.0002 |
| 3 | CTLA-4-directed Blocking Antibody [EPC] | 4 | 0.0001 |
| 4 | Anti-IgE [EPC] | 1 | 0.0000 |
| 5 | Platinum-based Drug [EPC] | 1 | 0.0000 |
| 6 | Benzodiazepine [EPC] | 1 | 0.0000 |
| 7 | Tumor Necrosis Factor Blocker [EPC] | 1 | 0.0000 |